A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke
Primary Purpose
Stroke, Ischemic
Status
Unknown status
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Induction of neural stem cells
Sponsored by
About this trial
This is an interventional treatment trial for Stroke, Ischemic
Eligibility Criteria
Inclusion Criteria:
- Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study procedures.
- Men and women 30-65 years old.
- Women must have a negative serum pregnancy test, gestation age women practice an acceptable method of contraception.
- At least 12 months but no more than 60 months from time of hemorrhagic stroke, with a motor neurological deficit.
- Documented history of single hemorrhagic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement, with correlated findings by MRI.
- Modified Rankin Score of 2, 3 or 4.
- FMMS score of 55 or less, two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 5 point change in the FMMS.
- Two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 4 point change in the NIHSS.
- Able and willing to undergo post-physical therapy/rehabilitation.
Exclusion Criteria:
- Any disabling psychological or psychiatric disorders which may confound the study.
- History of more than one hemorrhagic stroke.
- History of another major neurological disease or injury.
- Cerebral soften lesion size >5cm in any one measurement.
- Myocardial infarction within the prior 3 months.
- History of seizures or current use of antiepileptic medication.
- History of peripheral nerve surgery, including Selective Dorsal Rhizotomy and Contralateral Seventh Cervical Nerve Transfer.
- Receipt of any investigational drug or device within 30 days.
- Receipt of any cell infusion other than blood transfusion.
Any concomitant medical disease or condition noted below:
- Coagulopathy.
- Active or history of malignancy.
- Primary or secondary immune deficiency.
- Persistent MRI artifact or unable to undergo MRI.
- Any condition that the Investigator or primary physician feels may interfere with participation in the study or may endanger the subject.
- Any condition that the surgeon feels may pose complications for the surgery.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
iNSC treatment group
Arm Description
Outcomes
Primary Outcome Measures
Incidence of Treatment Emergent AE
Secondary Outcome Measures
Full Information
NCT ID
NCT03725865
First Posted
October 29, 2018
Last Updated
October 29, 2018
Sponsor
Allife Medical Science and Technology Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT03725865
Brief Title
A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke
Official Title
A Clinical Study of Intracerebral Transplantation of Human Peripheral Blood Derived Induced Neural Stem Cells for Cerebral Hemorrhagic Stroke
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Unknown status
Study Start Date
March 2019 (Anticipated)
Primary Completion Date
March 2019 (Anticipated)
Study Completion Date
March 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Allife Medical Science and Technology Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a single centre、single arm、open-label,to investigate the safety and efficacy of induction of neural stem cells transplantation in the brain
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Ischemic
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
iNSC treatment group
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
Induction of neural stem cells
Intervention Description
Brain injection iNSC
Primary Outcome Measure Information:
Title
Incidence of Treatment Emergent AE
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study procedures.
Men and women 30-65 years old.
Women must have a negative serum pregnancy test, gestation age women practice an acceptable method of contraception.
At least 12 months but no more than 60 months from time of hemorrhagic stroke, with a motor neurological deficit.
Documented history of single hemorrhagic stroke in subcortical region of MCA or lenticulostriate artery with or without cortical involvement, with correlated findings by MRI.
Modified Rankin Score of 2, 3 or 4.
FMMS score of 55 or less, two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 5 point change in the FMMS.
Two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 4 point change in the NIHSS.
Able and willing to undergo post-physical therapy/rehabilitation.
Exclusion Criteria:
Any disabling psychological or psychiatric disorders which may confound the study.
History of more than one hemorrhagic stroke.
History of another major neurological disease or injury.
Cerebral soften lesion size >5cm in any one measurement.
Myocardial infarction within the prior 3 months.
History of seizures or current use of antiepileptic medication.
History of peripheral nerve surgery, including Selective Dorsal Rhizotomy and Contralateral Seventh Cervical Nerve Transfer.
Receipt of any investigational drug or device within 30 days.
Receipt of any cell infusion other than blood transfusion.
Any concomitant medical disease or condition noted below:
Coagulopathy.
Active or history of malignancy.
Primary or secondary immune deficiency.
Persistent MRI artifact or unable to undergo MRI.
Any condition that the Investigator or primary physician feels may interfere with participation in the study or may endanger the subject.
Any condition that the surgeon feels may pose complications for the surgery.
12. IPD Sharing Statement
Learn more about this trial
A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke
We'll reach out to this number within 24 hrs